Erilin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Erilin

Quick Facts

Property Description
Active Ingredient Sildenafil (as Sildenafil citrate)
Form Oral dosage form (e.g., film-coated tablets, oral suspension)
Pharmacological Class Phosphodiesterase-5 (PDE5) Inhibitor
General Purpose To facilitate vasodilation and enhance blood flow
Origin Synthetic compound

Identity, Classification, and Composition

Erilin is a synthetic, single-component prescription medicinal product whose therapeutic action is defined by its active ingredient, Sildenafil. This compound is classified as a highly selective Phosphodiesterase-5 (PDE5) Inhibitor. This classification, which is clinically recognized for efficacy in addressing certain vascular conditions, establishes Sildenafil as a core treatment option. Erilin is typically presented in an oral dosage form, such as a film-coated tablet, which is a distinctive feature of its presentation.

The primary identity of Sildenafil is established by its mechanism of blocking the PDE5 enzyme, thereby preserving the natural chemical messenger cyclic Guanosine Monophosphate (cGMP). This selective inhibitor mechanism translates into its general therapeutic effect. This means the medication operates precisely on specific biochemical pathways to produce its physiological effects, which are well-documented through research into the PDE5 class.

Form and General Purpose

Erilin is designed for the oral route of administration, supplied most commonly as an oral dosage form, ensuring convenient and standardized ingestion. The composition of the product includes Sildenafil as the therapeutic agent, alongside necessary pharmaceutical excipients that form the non-active base of the preparation.

The essential purpose of the PDE5 inhibitor class is to utilize the preserved cGMP to amplify signals for smooth muscle relaxation, which leads to localized vasodilation (widening of blood vessels). This targeted action at the peripheral site of action results in improved blood flow. This fundamental effect of Sildenafil is the basis for its general application in conditions where enhancing local circulation is medically necessary.

Regulatory References

  1. National Library of Medicine (NIH)

What side effects are possible with Erilin?

Possible Side Effects and Safety Information for Erilin

Adverse reactions associated with Erilin are documented and continuously monitored through global regulatory surveillance systems, including those governed by the European Medicines Agency (EMA) and national Competent Authorities. The drug's safety profile is compiled from clinical trials and post-marketing experience.

Adverse Reaction Summary

Classification Examples of Adverse Reactions (Typically Common/Very Common)
Gastrointestinal Diarrhea, nausea, vomiting, indigestion, abdominal pain.
General Disorders Fatigue, weakness, or general tiredness.
Blood/Lymphatic System Changes in laboratory values (e.g., decreased white blood cell count, as is possible with some drug classes).

Clinically Significant and Serious Reactions

  • Hypersensitivity: Severe allergic reactions (anaphylaxis) are rare but possible, requiring immediate medical attention.
  • Hepatobiliary: Abnormal liver function tests or, rarely, drug-induced liver injury, may necessitate monitoring.
  • Clostridioides difficile-associated diarrhea (CDAD): Like most antibiotics, Erilin carries a risk of developing this condition, which can range from mild diarrhea to severe colitis.
  • Serious Cardiac Effects: For related compounds (e.g., Eribulin mesylate), specific warnings exist regarding QT prolongation (a change in heart rhythm) which can lead to life-threatening arrhythmias. This requires caution, particularly in patients with pre-existing heart conditions or electrolyte imbalances.

Safety Considerations and Restrictions

  • Specific Populations: Caution is advised, and dose adjustment may be necessary in patients with impaired renal (kidney) or hepatic (liver) function, as these organs are key to drug clearance.
  • Population-Specific Data: Safety data for use during pregnancy and breastfeeding is subject to limited human studies and requires careful assessment of benefits versus potential risks by a healthcare provider.
  • Monitoring: Regular monitoring of blood cell counts and liver/kidney function may be required during the course of treatment, especially for prolonged use or in high-risk patients. All serious and unexpected adverse reactions must be reported to the relevant regulatory authority.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Erilin (Sildenafil) overdose focuses on documented manifestations resulting from exposure to doses higher than recommended. The primary clinical signs observed at increased exposure include decreased blood pressure (hypotension) and episodes of syncope (fainting), which are direct exaggerations of the drug's intended vasodilatory effect. Severe localized vascular outcomes, such as a prolonged erection (priapism), are also documented risks requiring urgent action.


Regulatory Overdose Presentation
Decreased blood pressure and Syncope
Prolonged erection (lasting four hours or more)
Sudden loss of vision or hearing

In cases of documented overdose, the mandated management approach is the application of standard supportive measures to address clinical symptoms as they arise. Regulatory authorities explicitly state that no specific antidote is known for sildenafil overdose. Furthermore, renal dialysis is not expected to accelerate clearance of the active substance from the body. Consequently, any severe or persistent clinical presentation, particularly a prolonged erection, sudden sensory loss, or signs of profound hypotension, constitutes a scenario where seeking immediate medical attention is required as defined by official labeling.

Therapeutic Uses of Erilin

Erilin is commonly used across conditions presenting with disruptive symptom manifestations related to systemic imbalance. The primary therapeutic uses include the management of Erectile Dysfunction and Pulmonary Arterial Hypertension (PAH).

For issues with sexual function, the medication is relevant in contexts marked by increased discomfort or tension and assists with maintaining functional stability. For chronic conditions like PAH, the medicine plays a role in managing groups of symptoms such as exertional shortness of breath and fatigue. By offering symptomatic relief, the treatment helps improve day-to-day comfort during symptomatic phases.

“It supports the patient during difficult episodes by easing distress.”

The treatment may assist with managing symptoms related to systemic imbalance and functional strain in appropriate clinical scenarios.

Quick Fact: Relief for Functional Strain
Primary Goal To help address symptom clusters that may become intense or disruptive in contexts requiring supportive management of functional difficulty.
Usage Context Applied in clinical settings that involve acute or unstable symptom patterns in conditions where functional stability becomes affected.

Eligibility and Restrictions for Use

Who Can and Cannot Use Erilin? (Sildenafil)

Official regulatory documents define strict population eligibility for Erilin, based on specific contraindications and required cautions.


Absolute Regulatory Contraindications

Erilin must not be used by patients who are currently taking organic nitrates (such as nitroglycerin) or nitric oxide donors, or by patients using guanylate cyclase stimulators (e.g., riociguat), due to the risk of severe hypotension. Use is also contraindicated in patients with a history of severe hypotension (< 90/50 mmHg), recent stroke or myocardial infarction, severe hepatic impairment (Child-Pugh Class C), or known hereditary degenerative retinal disorders (e.g., retinitis pigmentosa).


Conditional Use and Population Restrictions

Population Group Regulatory Status and Limitation
Organ Impairment Use requires caution in patients with severe renal or hepatic impairment; a lower starting dose should be considered for the Erectile Dysfunction indication.
Pediatric Patients Not indicated for individuals under 18 for Erectile Dysfunction. For Pulmonary Arterial Hypertension (PAH), regulatory positions differ: the US FDA generally recommends against use due to risk, while the EMA supports use at low doses.
Reproductive Status Not indicated for use in women for the Erectile Dysfunction indication. Use in pregnancy and lactation is generally not established and not recommended unless strictly necessary for PAH.
Other Conditions Use requires caution in patients with anatomical deformation of the penis or conditions predisposing to priapism (e.g., sickle cell disease).

What should I know about interactions with other medicines?

The official regulatory profile for Erilin (Sildenafil) is defined by pharmacokinetic and pharmacodynamic interactions that necessitate specific co-administration restrictions. The primary pharmacokinetic interaction involves CYP3A4-mediated metabolism. Strong CYP3A4 inhibitors, such as Ritonavir and Ketoconazole, significantly inhibit Sildenafil clearance, leading to a substantial increase in plasma exposure (AUC). For example, co-administration with Ritonavir increases Sildenafil exposure up to eleven-fold, which mandates a maximum single dose restriction of 25 mg within a 48-hour period.

From a pharmacodynamic perspective, Erilin’s effect as a vasodilator can be potentiated by certain drug classes. Co-administration with Organic Nitrates and Guanylate Cyclase (sGC) Stimulators (like Riociguat) is formally contraindicated due to the high risk of severe, uncontrolled hypotension. Additive blood pressure lowering effects are also documented with Alpha-Blockers, requiring initiation at the lowest Sildenafil dose (25 mg).

Interactions with non-medicinal substances also exist. A high-fat meal has been found to delay the rate of absorption. Furthermore, Grapefruit Juice can increase Sildenafil plasma levels, while Alcohol (ethanol) may potentiate its hypotensive effects. Regulatory documents also note that reduced clearance in patients with severe hepatic or renal impairment increases overall drug exposure, heightening the susceptibility to these documented interactions.

Mechanism of Action

How Erilin Works

Erilin's mechanism is defined by the selective competitive inhibition of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is primarily responsible for the degradation of the cellular messenger cyclic Guanosine Monophosphate (cGMP) in vascular smooth muscle cells. By occupying the enzyme's active site, the active ingredient prevents the hydrolysis of cGMP, thereby preserving the existing signal.

The drug's action is critically dependent on the body's natural release of Nitric Oxide (NO), which initiates cGMP synthesis. Erilin subsequently amplifies this endogenous NO-cGMP cascade by sustaining the elevated cGMP concentration. This persistent elevation activates downstream signaling sequences, leading directly to the relaxation of the vascular smooth muscle.

This cellular relaxation results in localized vasodilation (arterial widening). The systemic change in blood flow dynamics is characterized by increased blood inflow to specific vascular beds. The mechanism is constrained by a measurable affinity for the related enzyme PDE6, an example of mechanistic selectivity.

Dosage and Administration Information

How to Use Erilin

The usage of Erilin (Sildenafil) is structured into distinct protocols that depend on the condition being managed. The medicine is primarily taken via the oral route, administered either as a film-coated tablet or, in some contexts, as a reconstituted oral suspension. An intravenous (IV) formulation is approved for temporary substitution in specific clinical scenarios, such as when a patient with Pulmonary Arterial Hypertension (PAH) cannot tolerate oral intake.


Official Dosing and Frequency

Administration frequency and dosage ranges are set according to the labeled use, and patients must only be treated with one sildenafil product at a time.

Usage Context Standard Dosing Regimen Frequency Pattern
Erectile Dysfunction (ED) Starting dose of 50 mg, adjustable from 25 mg to a maximum of 100 mg per dose. Taken as needed, not more than once per day.
Pulmonary Arterial Hypertension (PAH) 20 mg (oral) or 10 mg (IV) per dose. Administered on a fixed schedule three times a day (TID).

Administration Details

Oral doses can be taken with or without food. However, for ED use, consumption with a high-fat meal may result in a delayed onset of action. When the oral suspension is used, it is required that the product be shaken well for 10 seconds before each dose is measured.

For certain patient groups, including older adults (ge 65 years) and individuals with severe hepatic or renal impairment, it is recommended that a lower initial dose of 25 mg be considered when used for the ED indication.

Recent Clinical Evidence

Research evidence / Overview of studies for Erilin

Evidence for Use in Erectile Dysfunction (ED)

The evidence landscape for Sildenafil (Erilin) in the context of Erectile Dysfunction (ED) is largely built upon multiple short-term, placebo-controlled, Randomized Controlled Trials (RCTs). These studies focused on outcomes reflecting daily functioning and patient-reported experiences. Research examined changes in the ability to achieve and maintain an erection sufficient for sexual activity, as well as patient assessments of overall function.

Studies monitored responses over defined time intervals, typically ranging from four to twelve weeks, with some long-term extension studies monitoring the product's use over periods up to three years. Studies reported measurements where patterns observed in the group receiving Sildenafil differed from the group receiving a placebo across several outcomes related to functional measures. Certain regulatory summaries note that reported outcomes were observed to be less consistent in men with specific underlying conditions, such as those who have undergone radical prostatectomy or who have severe diabetes.


Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Sildenafil was evaluated in PAH in research contexts involving fluctuating or unstable symptoms. The evidence landscape for PAH includes short-term RCTs, systematic reviews, and long-term observational settings evaluating daily-life functioning. Research monitored outcomes related to functional capacity, such as changes in the distance a patient can walk in six minutes (6MWD), and the time elapsed before a patient experienced clinical worsening.

Data show patterns related to measured changes in functional capacity were observed in the Sildenafil group compared to the placebo group across defined time intervals. Research contributes to the broader evidence landscape related to conditions marked by physiological strain.


What is Still Uncertain About the Research

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Comparative evidence is lacking for direct, large-scale comparisons between Sildenafil and all other contemporary PDE5 inhibitors for both ED and PAH. Additionally, for PAH, data are still emerging regarding reported outcomes when Sildenafil is used in combination with all other available advanced therapies, meaning certainty remains low in certain combination treatment scenarios.

Frequently Asked Questions (FAQ)

Common questions about Erilin (FAQ)


Q: What is the main difference between Erilin and other medicines used for the same condition?

Official information states that the active ingredient, Sildenafil, is classified as a Phosphodiesterase type 5 (PDE5) inhibitor. Regulatory research summaries note a lack of direct, large-scale studies comparing Sildenafil to all other contemporary medicines in the same class for both its authorized uses. Therefore, the available evidence is focused on the drug's effects versus placebo.


Q: Is Erilin considered a controlled substance or habit-forming drug?

No, the active ingredient in Erilin, Sildenafil, is not scheduled as a controlled substance. According to the US Drug Enforcement Administration (DEA), this medication is categorized as having no schedule.


Q: Does Erilin treat the root cause of the condition or only manage the symptoms?

The drug's mechanism is described by official documents as the selective inhibition of the PDE5 enzyme, which helps to relax and widen blood vessels (vasodilation). This physiological effect is intended to manage and enhance blood flow for the treated conditions.


Q: How quickly should I expect to notice the effects of Erilin?

For its use in Erectile Dysfunction, the medication is typically taken approximately one hour before the activity. Official guidance states that the drug can be taken anywhere between 30 minutes and 4 hours prior to use.


Q: What is the typical length of time a patient takes Erilin for?

Official documents do not define an optimal duration of therapy, as it can vary widely based on the treated condition and individual needs. However, long-term clinical extension studies have monitored the continued use of the product over periods lasting from six months up to four years.


Q: Is it normal to feel slight nausea or a headache when first starting Erilin?

Yes, headache and nausea are listed among the common adverse reactions reported in clinical trials. Regulatory documents report headache and dyspepsia (indigestion or upset stomach, which can include nausea) as reactions that occurred more frequently than placebo.


Q: Are the serious side effects of Erilin considered to be very rare?

Regulatory warnings indicate that the clinically significant adverse effects are generally considered to be rare. Specific serious events like severe allergic reactions (hypersensitivity) and sudden vision loss (NAION) are described in the official label as rare conditions or possibilities.


Q: Does Erilin interact with any popular dietary or herbal supplements, such as St. John's Wort?

Yes, Erilin’s metabolism can be affected by certain herbal products. Regulatory warnings note that supplements like St. John's wort can lower the blood levels and effects of Sildenafil by interacting with a specific liver enzyme.


Q: Are there any specific foods or beverages that need to be avoided while using Erilin?

Regulatory documents advise caution regarding certain intake. For its use in Erectile Dysfunction, consuming the dose with a high-fat meal may lead to a delay in the onset of the drug’s action. Additionally, some official sources note that Grapefruit juice may increase the level of Sildenafil in the blood.


Q: Is there a generic version of Erilin available, and is it equally effective?

Yes, the active ingredient, Sildenafil, is available in generic versions. Regulatory bodies, such as the European Medicines Agency (EMA), consider these generic products to be bioequivalent to the original medicine. Bioequivalence means that the generic formulation is determined by regulatory bodies to provide the same clinical benefits and risks as the reference medicine.


Q: What should be done if a scheduled dose of Erilin is missed?

For the treatment of Pulmonary Arterial Hypertension (PAH), which is a scheduled dose, official patient information states that a missed dose is generally taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose is generally omitted, and patients are advised to resume their usual schedule.


Q: Is it safe to crush or split Erilin tablets if there is difficulty swallowing them whole?

The safety of splitting or crushing tablets depends entirely on whether the medication is officially scored (designed with a dividing line) and evaluated by the manufacturer. The safety of altering the tablet should be confirmed by consulting the official product information.


Q: Is it possible for the effectiveness of Erilin to decrease after long-term use?

Long-term studies have reported no evidence of tachyphylaxis (a term used for a decreased response over time) during the continued use of the drug. This finding covers study periods lasting up to four years.


Q: Does Erilin contain any known allergens or inactive ingredients that can cause a reaction?

Official regulatory documents state that the drug is contraindicated (must not be used) in patients with a known hypersensitivity (severe allergic reaction) to Sildenafil. This prohibition also extends to any other component of the tablet, including the inactive ingredients (excipients).


Q: Can taking Erilin affect a person's ability to drive or operate heavy machinery?

The regulatory label lists side effects such as dizziness and abnormal vision (which includes blurred vision). Patients who experience these effects should exercise caution when driving or operating heavy machinery.


Q: Does Erilin interact with commonly used medicines for acid reflux or heartburn?

Pharmacodynamic research has noted that Sildenafil may affect the function of the lower esophageal sphincter and alter the movement of the esophagus. This area of effect may be relevant to patients with concerns about acid reflux or heartburn.


Q: If I feel well after a few days, can I assume Erilin has worked and stop taking it?

The usage pattern depends on the condition. The medication is taken as needed for Erectile Dysfunction, but for Pulmonary Arterial Hypertension, it requires a fixed, scheduled dose. For fixed schedules, patients typically continue taking the medicine as prescribed unless their healthcare provider suggests a change.

How should Erilin be stored and disposed of?

How to Store and Dispose of Erilin?

The storage and disposal instructions for Erilin (sildenafil oral tablets) are derived strictly from official regulatory labeling to ensure product integrity and patient safety.

Storage Conditions

Requirement Official Regulatory Rule
Temperature Store at room temperature, not exceeding 30 C (86 F).
Protection Keep in the original container, tightly closed, to protect the tablets from moisture.
Child Safety The medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Erilin must be disposed of in accordance with local requirements for pharmaceutical waste. Authorities generally recommend utilizing an official drug take-back program. If no program is available, the tablets should be mixed with an undesirable substance, sealed, and discarded in the household trash as per government guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Erilin found in:

A-Z Index: